Introduction
============

Cancer is a major disease burden worldwide, with high morbidity and mortality rates compounded by the economic burden of maintaining patient quality-of-life and lengthening survival period.[@b1-cmar-9-821],[@b2-cmar-9-821] To date, many predictive biomarkers with excellent prognostic utility have been discovered for various cancers. Targeted molecular therapy and cancer immunotherapy have been introduced to improve disease management.[@b3-cmar-9-821]--[@b6-cmar-9-821] One such biomarker is a cell surface protein known as trophoblast cell surface antigen 2 (TROP2),[@b7-cmar-9-821] also called "tacstd2", "m1s1 protein", "tumor-associated calcium signal transducer 2", "tumor-associated antigen ga733-1", "ga733-1 antigen", "membrane component 1 surface marker 1", "epithelial glycoprotein 1", and "gastrointestinal antigen 733-1".[@b8-cmar-9-821] This protein shows relatively low expression in normal epithelial cells and is overexpressed in various types of human cancers.[@b9-cmar-9-821]--[@b23-cmar-9-821] Overexpression of TROP2 in cancer has been linked to disease aggression and shorter overall survival (OS). Several clinical studies have demonstrated that therapies targeting TROP2-benefited cancer patients by inhibiting TROP2 expression[@b24-cmar-9-821]--[@b33-cmar-9-821] and have explored this protein as a potential predictor of cancer prognosis. However, due to small sample size, the results were not categorically conclusive.[@b13-cmar-9-821],[@b15-cmar-9-821],[@b23-cmar-9-821],[@b34-cmar-9-821]--[@b46-cmar-9-821] The first meta-analysis about TROP2 was published 1 year ago,[@b47-cmar-9-821] which indicated that TROP2 overexpression was associated with poor survival in human solid tumors. Some new relevant studies have been published since then, therefore, we performed this meta-analysis to systematically review and gather more powerful evidence to verify the relationship between TROP2 overexpression and clinical characteristics/prognosis in patients with a variety of human cancers.

Methods
=======

Search strategy
---------------

Articles related to TROP2 and carcinomas were retrieved from online databases: Embase, PubMed, ISI Web of Science, China National Knowledge Infrastructure (CNKI), and Wan-Fang Data Knowledge Service Platform (WanFang Data). The Medical Subject Headings (MeSH) search terms were as follows: "tacstd2" or "m1s1 protein" or "tumor-associated calcium signal transducer 2" or "trop2" or "tumor-associated antigen ga733-1" or "ga733-1 antigen" or "trop-2" or "trophoblast cell surface antigen 2" or "membrane component 1 surface marker 1" or "epithelial glycoprotein 1" or "gastrointestinal antigen 733-1" and "cancer" or "tumor" or "carcinoma" or "neoplasm". We additionally retrieved references cited in the articles and included them in the study. The last search was performed on September 23, 2017.

Selection criteria
------------------

Studies that 1) investigated the relationship between TROP2 and patient prognosis; 2) provided available data to obtain or calculate risk ratio (RR) or hazard ratio (HR) for survival and 95% confidence interval (CI); and 3) had clear statement about TROP2 expression state as "high" and "low" or "positive" and "negative" were included in this meta-analysis.

Exclusion criteria were (1) published letters, editorials, abstracts, reviews, case reports and expert opinions; (2) experiments not performed on patients; and (3) articles without the HRs and 95% CI or K--M survival curves about patients' prognostic outcomes.

Data extraction
---------------

The following data were extracted from each publication: first author, year of publication, country, tumor type, clinical stage, sample size, age of patients, analysis method, follow-up period, outcome, parameter cutoff values, survival analysis, estimates such as HRs or RRs concerning the overexpression of TROP2 in terms of OS, disease-free survival (DFS)/progression-free survival (PFS), disease recurrence (DR), and patient clinical characteristics. The HRs or RRs and their 95% CIs were extracted from the original papers directly if available (23 articles, 25 studies). Otherwise, relevant data such as sample number in test groups, log-rank statistics, and *p* value were used to calculate the variable (3 studies[@b48-cmar-9-821]--[@b50-cmar-9-821]). Alternatively, the approximate HRs (1 study[@b15-cmar-9-821]) were calculated according to the Zhou ZR's statistical method from the Kaplan--Meier survival curves.[@b51-cmar-9-821] The Engauge Digitizer version 4.1 was used for this analysis.

Statistical analysis
--------------------

The extracted HRs/RRs were summarized as pooled HR and 95% CI values, using Stata, version 12.0. The fixed-effects model was used at first to calculate the heterogeneity and construct forest plots. For inconsistency tests, *I*^2^ \> 50% and *p* \< 0.05 were considered statistically significant. Larger values of *I*^2^ indicated higher heterogeneity. The fixed-effects model was subsequently used when heterogeneity was not significant (\<50%).[@b52-cmar-9-821] We conducted subgroup analysis and sensitivity analysis to compensate for statistical heterogeneity. Graphical funnel plots were generated, and Begg's test and Egger's test were performed to assess the extent of publication bias by visual inspection or by quantitative evaluation.[@b53-cmar-9-821],[@b54-cmar-9-821]

Results
=======

Study selection and characteristics
-----------------------------------

As shown in [Figure 1](#f1-cmar-9-821){ref-type="fig"}, a total of 1,155 articles were identified initially. After excluding 515 duplicates, titles/abstracts of 640 studies were reviewed. Of these, 167 articles were not related to the research objective, 435 articles were not performed on patients and 3 were systematic reviews. Thirty-five articles were reviewed further. Three articles were not available to get full text, and five papers did not provide applicable data for meta-analysis. We handpicked the remaining 27 articles eligible for this meta-analysis. The studies by Inamura estimated the roles of TROP2 in cancer prognosis among 3 different lung cancer subtypes (adenocarcinoma, squamous cell carcinoma, and high-grade neuroendocrine tumor), and thus it was regarded as 3 independent studies.[@b55-cmar-9-821] The main characteristics of these studies are presented in [Table 1](#t1-cmar-9-821){ref-type="table"}. All included studies were published from 2006 to 2017. There were 17 studies from China, 5 from Japan, 3 from Austria, 3 from Italy, and 1 from South Korea. A total of 4,852 patients were enrolled (sample size: maximum: 702, minimum: 47, and mean: 167), and 16 carcinoma types were analyzed, including lung cancer (6, different subtypes), colorectal cancer (4), bladder cancer (2), breast cancer (2), gallbladder cancer (2), gastric cancer (2), ovarian carcinoma (2), cervical cancer (1), endometrioid endometrial carcinoma (1), extranodal natural killer (NK)/T cell lymphoma/nasal type (1), hilar cholangiocarcinoma (1), laryngeal squamous cell carcinoma (1), nasopharyngeal carcinoma (1), pancreatic cancer (1), pituitary adenomas (1), and squamous cell carcinoma of oral cavity (1). A total of 47 HRs/RRs were extracted from 29 studies, including 26 for OS, 6 for DFS,[@b15-cmar-9-821],[@b34-cmar-9-821],[@b35-cmar-9-821],[@b41-cmar-9-821],[@b44-cmar-9-821],[@b56-cmar-9-821] 5 for PFS,[@b13-cmar-9-821],[@b34-cmar-9-821],[@b35-cmar-9-821],[@b39-cmar-9-821],[@b57-cmar-9-821] 4 for DR,[@b38-cmar-9-821],[@b49-cmar-9-821],[@b57-cmar-9-821],[@b58-cmar-9-821] 3 for CSS,[@b55-cmar-9-821] and 1 for DFS/PFS.[@b59-cmar-9-821] Study quality was evaluated by using the Newcastle--Ottawa Scale (NOS), and the quality scores ranged from 6 to 9, suggesting high methodological quality.

Relationship between the expression of TROP2 and patients' OS
-------------------------------------------------------------

Our analysis revealed a positive link between TROP2 overexpression and OS (pooled HR: 1.84, 95% CI: 1.45--2.35), with heterogeneity (*I*^2^ = 67.3%; *p* = 0.000), indicating that higher level of TROP2 expression could predict shorter OS outcomes ([Figure 2](#f2-cmar-9-821){ref-type="fig"} and [Table 2](#t2-cmar-9-821){ref-type="table"}). In subgroup analysis according to geographical location, HRs were greater than 1.0 in the population from China, Austria, with low heterogeneity, in agreement with previous studies (China: *I*^2^ = 43.0%, *p* = 0.044; Austria: *I*^2^ = 0.0%, *p* = 0.762) ([Figure 2](#f2-cmar-9-821){ref-type="fig"}). While HRs of Japan and Italy were not statistically significant ([Figure 2](#f2-cmar-9-821){ref-type="fig"}), the results of the sensitivity analysis showed that the association between TROP2 and OS was stable, and the studies by Ambrogi et al,[@b49-cmar-9-821] Inamura et al[@b55-cmar-9-821] affected results greatly ([Figure 3](#f3-cmar-9-821){ref-type="fig"}). After excluding these 2 studies (Ambrogi and Inamura (c)) one by one, the heterogeneity decreased significantly (without Ambrogi: *I*^2^ = 51.8%, *p* = 0.002; without Ambrogi and Inamura (c): *I*^2^ = 28.1%, *p* = 0.100) ([Figure 4A and B](#f4-cmar-9-821){ref-type="fig"}). The publication bias evaluation is shown in [Figure 5](#f5-cmar-9-821){ref-type="fig"} (Egger's test: *p* = 0.048; Begg's test: *p* = 0.217). According to Shi's conclusions,[@b65-cmar-9-821] we thought that there is no significant publication bias.

Relationship between TROP2 expression and patient outcomes
----------------------------------------------------------

There were 6 studies, 5 studies, 4 studies, 3 studies, and one related to the association between TROP2 expression and DFS, PFS, DR, CSS, and DFS/PFS, respectively. We found that the overexpression of TROP2 was a potential negative prognostic factor for DFS (pooled HR: 2.77, 95% CI: 1.73--4.42) and PFS (pooled HR: 1.71, 95% CI: 1.25--2.35), with low heterogeneity between studies (DFS: *I*^2^ =20.8%, *p* = 0.277; PFS: *I*^2^ =0.0%, *p* = 0.809; random model) ([Figure 6A](#f6-cmar-9-821){ref-type="fig"}). The association between TROP2 and DR or CSS was not significant (DR: pooled HR: 1.44, 95% CI: 0.59--3.52; *I*^2^ =86.7%, *p* = 0.000; CSS: pooled HR: 0.65, 95% CI: 0.24--1.76; *I*^2^ =75.7%, *p* = 0.016; random model) ([Figure 6A](#f6-cmar-9-821){ref-type="fig"}). The publication bias analyses were performed, and no significant publication bias was found (Egger's test: *p* = 0.297; Begg's test *p* = 0.624) ([Figure 6B](#f6-cmar-9-821){ref-type="fig"}).

Relationship between TROP2 overexpression and clinical characteristics
----------------------------------------------------------------------

[Table 3](#t3-cmar-9-821){ref-type="table"} shows the patient clinical characteristics, including sex, age, lymph node metastasis, distant metastasis, TNM stage, and differentiation. Our results ([Table 2](#t2-cmar-9-821){ref-type="table"}) showed that TROP2 overexpression correlated with moderate/poor differentiation (pooled HR: 3.03, 95% CI: 1.99--4.63), distant metastasis (pooled HR: 2.46, 95% CI: 1.05--5.75), lymph node metastasis (pooled HR: 2.47, 95%: CI 1.72--3.56), and advanced TNM stage (pooled HR: 2.02, 95% CI: 1.38--2.95) ([Figure 7A--D](#f7-cmar-9-821){ref-type="fig"}), with a certain heterogeneity (all: *I*^2^ = 52.7--61.2%, *p* = 0.001--0.076). The sex and age of patients were not significantly linked to the expression level of TROP2 (sex: pooled HR: 1.08, 95% CI: 0.90--1.29; age: pooled HR: 0.94, 95% CI: 0.79--1.11).

Discussion
==========

This meta-analysis contained data from 4,852 participants, evaluated in 27 articles (29 studies). Overall analysis and subgroup analysis were performed. The results clearly showed that overexpression of TROP2 is significantly associated with poor OS, DFS, PFS, as well as the following clinical characteristics: moderate/poor tumor differentiation, lymph node metastasis, the presence of distant metastasis, and advanced TNM stage. Although some significant heterogeneity was found, the association between TROP2 and cancers was stable, just as sensitivity analysis and publication bias evaluation showed. We found that the studies by Ambrogi et al[@b49-cmar-9-821] and Inamura et al[@b55-cmar-9-821] put forward opposite views from the other studies, then we checked them carefully and no obvious error or defect was found. That is why we made this meta-analysis due to the urgent need of further studies with larger sample sizes.

This meta-analysis has both strengths and limitations. A larger sample size compared to a previous study[@b47-cmar-9-821] (27 vs 16 articles, 4,852 vs 2,569 patients) powered the study effectively and increased the reliability of the results. However, most of the included papers are retrospective observational studies without control groups. In addition, there were inconsistencies among studies in defining important terms such as: "the overexpression of TROP2", "the TNM stage", "differentiation", and "the cut-off value for age". Another limitation of this study is that, in some cases, values were indirectly obtained from survival curves or were calculated using related data, probably resulting in some bias because of analytical errors. Furthermore, a wide range of the publication dates meant that other biases may have been introduced due to gradual improvements in detection techniques, surgical efficacy, safety, and medical treatment over time. These limitations were unavoidable and could only be addressed by performing more studies with larger sample sizes.

Currently, the mechanism of TROP2 signaling and its function remain uncertain. The proposed mechanisms of TROP2 action are as follows: regulating calcium levels via protein kinase C (PKC) mitogenic signaling pathway, modulating extracellular regulated protein kinases (ERK) signaling, decreasing cell adhesion to fibronectin via integrin pathway, regulating gene expression via intramembrane proteolysis, causing neuregulin 1 (NRG1) release, and activating the epidermal growth factor family receptor, ErbB3.[@b8-cmar-9-821] Studies in zebrafish and mice have elucidated the role of TROP2 in the development of lung, intestines, and kidney.[@b66-cmar-9-821],[@b67-cmar-9-821] These studies have revealed the role of TROP2 in promoting cell proliferation and organ development. A number of clinical studies overwhelmingly confirmed a strong association between TROP2 expression levels and tumor proliferation, aggressiveness, invasiveness, and metastasis, so they pointed out that TROP2 can be used as a biomarker for clinical diagnosis and to predict prognosis.[@b9-cmar-9-821],[@b31-cmar-9-821],[@b35-cmar-9-821],[@b37-cmar-9-821],[@b39-cmar-9-821],[@b42-cmar-9-821],[@b46-cmar-9-821],[@b68-cmar-9-821] Furthermore, recombinant antibodies against TROP2 have been used to treat cancers by inhibiting TROP2 expression or by destroying cancer cells directly. Results from such studies have confirmed the efficacy of TROP2 targeted therapies.[@b24-cmar-9-821]--[@b33-cmar-9-821] However, normal-born TROP2-knockout mice can survive and grow to adulthood, which means that TROP2 may not be vital for organ and body development, or that its function can be taken over by other proteins.[@b69-cmar-9-821] In addition, one study has shown that tumorigenesis may result as a consequence of defective TROP2.[@b70-cmar-9-821]

Conclusion
==========

Thus, the function and the mechanisms of action of TROP2 are not clear yet, while the relationship between TROP2 and cell proliferation is complex, possibly determined by tissue type and context.[@b8-cmar-9-821],[@b55-cmar-9-821] Further research studies with larger sample sizes should be conducted to learn and confirm its role in cancer occurrence, development, and mechanism of action. In conclusion, the expression of TROP2 is associated with cancer disease, maybe a potential diagnostic indicator and prognostic biomarker.
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![Overall analysis and subgroup analysis about patients' overall survival.\
**Notes:** The segments represent the 95% CI of each study. The diamonds represent the overall effect sizes, and the diamond widths represent the overall 95% CIs.\
**Abbreviations:** CI, confidence interval; HR, hazard ratio; NA, not applicable.](cmar-9-821Fig2){#f2-cmar-9-821}

![Sensitivity analysis to assess the effect of each study of the meta-analysis about the overall survival (random model).\
**Abbreviation:** CI, confidence interval.](cmar-9-821Fig3){#f3-cmar-9-821}

###### 

Overall analysis of the correlation between TROP2 expression and patients' OS after excluding the significant studies which held opposite views.

**Notes:** (**A**) Without Ambrogi[@b49-cmar-9-821] and (**B**) without Ambrogi[@b49-cmar-9-821] and Inamura (c).[@b55-cmar-9-821]

**Abbreviations:** CI, confidence interval; HR, hazard ratio; OS, overall survival.
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![Begg's funnel plot for the studies involved in meta-analysis about the overall survival.\
**Abbreviations:** HR, hazard ratio; SE, standard error.](cmar-9-821Fig5){#f5-cmar-9-821}

###### 

The meta-analysis and Begg's funnel plot of the correlation between TROP2 expression and patients' DFS/PFS/CSS/DR.

**Notes:** (**A**) The correlation between TROP2 expression and patients' DFS/PFS/CSS/DR. (**B)** Begg's funnel plot for the studies involved in meta-analysis about DFS/PFS/CSS/DR (random model).

**Abbreviations:** CSS, cancer-specific survival; DR, disease recurrence; DFS, disease-free survival; PFS, progression-free survival; TROP2, trophoblast cell surface antigen 2; NA, not applicable.
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###### 

The correlation between TROP2 expression and carcinoma patients' clinicopathologic features.

**Notes:** (**A)** Differentiation (moderate/poor vs well); (**B)** distant metastasis (present vs absent); (**C)** lymph node metastasis (present vs absent); and (**D)** TNM stage (III + IV vs I + II).

**Abbreviations:** CI, confidence interval; OR, odds ratio; TNM, The TNM Classification of Malignant Tumours; TROP2, trophoblast cell surface antigen 2.
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###### 

Main characteristics of the eligible studies in this meta-analysis

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                             Year   Tumor type                                 Country       Sample size   Age of the patients (years, median and range)   Clinical stage of tumor                           Method          Cutoff value                                                 Follow-up (months) (median and range)         Outcome   Survival analysis       NOS
  ---------------------------------- ------ ------------------------------------------ ------------- ------------- ----------------------------------------------- ------------------------------------------------- --------------- ------------------------------------------------------------ --------------------------------------------- --------- ----------------------- -----
  Ambrogi et al[@b49-cmar-9-821]     2014   Breast cancer                              Italy         702           NA                                              TNM T~1--3~N~x~M0                                 IHC             Low ≤ 5%\                                                    96                                            OS\       Univariate analysis\    6
                                                                                                                                                                                                                                     High \> 86%                                                                                                DR        Multivariate analysis   

  Bignotti et al[@b34-cmar-9-821]    2010   Ovarian carcinoma                          Italy         104           55 (47--69)                                     FIGO stage WHO                                    IHC             Low = score 0--2\                                            28.5 (7.3--77.7)                              OS\       Univariate analysis\    8
                                                                                                                                                                                                                                     High = score 3                                                                                             DFS\      Multivariate analysis   
                                                                                                                                                                                                                                                                                                                                                PFS                               

  Bignotti et al[@b35-cmar-9-821]    2012   Endometrioid endometrial carcinoma         Italy         103           NA                                              FIGO stage WHO                                    IHC             Low = score 0--2\                                            48.7 (6.1--124.9)                             OS\       Univariate analysis\    7
                                                                                                                                                                                                                                     High = score 3                                                                                             DFS\      Multivariate analysis   
                                                                                                                                                                                                                                                                                                                                                PFS                               

  Chen et al[@b36-cmar-9-821]        2014   Gallbladder cancer                         China         93            NA                                              TNM I--IV                                         IHC             Low = score 0--3\                                            NA                                            OS        Univariate analysis\    8
                                                                                                                                                                                                                                     High = score 4--9                                                                                                    Multivariate analysis   

  Chen et al[@b37-cmar-9-821]        2013   Extranodal NK/T cell lymphoma/nasal type   China         90            50.3 (25--71)                                   Ann Arbor Stage I--IV                             IHC             Low = score 0--3\                                            NA                                            OS        Multivariate analysis   8
                                                                                                                                                                                                                                     High = score 4--9                                                                                                                            

  Chen et al[@b59-cmar-9-821]        2014   Pituitary adenomas                         China         72                                                            NA                                                IHC             Low TIS ≤ 4\                                                 NA                                            DFS/PFS   Multivariate analysis   6
                                                                                                                                                                                                                                     High TIS = 5--9                                                                                                                              

  Fang et al[@b38-cmar-9-821]        2009   Colon cancer                               China         620           59 (15--86)                                     TNM I--IV                                         IHC             Immunoreactivity rating of II or III; moderate/strong        52 (1--130)                                   OS\       Multivariate analysis   9
                                                                                                                                                                                                                                                                                                                                                DR                                

  Fong et al[@b39-cmar-9-821]        2008   Pancreatic cancer                          Austria       197           65 (37--91)                                     TNM I--IV                                         IHC             Low = score 0--4\                                            9 (1--68)                                     OS\       Multivariate analysis   7
                                                                                                                                                                                                                                     High = score 5--12                                                                                         PFS                               

  Fong et al[@b40-cmar-9-821]        2008   Squamous cell carcinoma of oral cavity     Austria       90            63.4 (25--85)                                   TNM I--IV                                         IHC             Low = score 0--4\                                            23.8 (1--245)                                 OS        Univariate analysis\    8
                                                                                                                                                                                                                                     High = score 5--12                                                                                                   Multivariate analysis   

  Guan et al[@b41-cmar-9-821]        2015   Nasopharyngeal carcinoma                   China         58            45 (24--72)                                     TNM I--IV                                         IHC             Low = score 0--1.5\                                          96 (1--161)                                   OS\       Univariate analysis\    8
                                                                                                                                                                                                                                     High = score 2--3                                                                                          DFS       Multivariate analysis   

  Inamura[@b55-cmar-9-821]           2017   Lung cancer ADC                            Japan         270           NA                                              The 7th edition of the AJCC- TNM staging system   IHC             No/low: In intensity 1 \<\                                   13.0 (9.1--15.5) years                        CSS\      Univariate analysis\    8
                                                                                                                                                                                                                                     50% and intensity 2 \< 10%\                                                                                OS        Multivariate analysis   
                                                                                                                                                                                                                                     High: intensity 1 ≥ 50% or intensity 2 ≥ 10%                                                                                                 

  Inamura[@b55-cmar-9-821]           2017   Lung cancer SqCC                           Japan         201           NA                                              The 7th edition of the AJCC- TNM staging system   IHC             No/low: in intensity 1 \<\                                   5.0 (3.1--6.3) years                          CSS\      Univariate analysis\    8
                                                                                                                                                                                                                                     50% and intensity 2 \< 10%\                                                                                OS        Multivariate analysis   
                                                                                                                                                                                                                                     High: intensity 1 ≥ 50% or intensity 2 ≥ 11%                                                                                                 

  Inamura[@b55-cmar-9-821]           2017   Lung cancer HGNET                          Japan         115           NA                                              The 7th edition of the AJCC- TNM staging system   IHC             No/low: in intensity 1 \<\                                   5.8 (3.1--8.2) years                          CSS\      Univariate analysis\    8
                                                                                                                                                                                                                                     50% and intensity 2 \< 10%\                                                                                OS        Multivariate analysis   
                                                                                                                                                                                                                                     High: intensity 1 ≥ 50% or intensity 2 ≥ 12%                                                                                                 

  Jiang et al[@b48-cmar-9-821]       2013   Lung cancer NSCLC                          China         87            (58.6 ± 9.8)                                    TNM III~b~ IV                                     IHC             Low = score 0--3\                                            15.197 (13.688--16.706)                       OS        Multivariate analysis   6
                                                                                                                                                                                                                                     High = score 4--9                                                                                                                            

  Kobayashi et al[@b43-cmar-9-821]   2010   Lung cancer ADC                            Japan         130           60.7 (38--82)                                   Noguchi Classification A--F                       IHC             Low = score 0--4\                                            NA                                            OS        Multivariate analysis   8
                                                                                                                                                                                                                                     High = score 5--12                                                                                                                           

  Li[@b60-cmar-9-821]                2017   Gallbladder cancer                         China         88            NA                                              TNM I--IV                                         IHC             Low = score 0--3\                                            36.75                                         OS        Univariate analysis\    6
                                                                                                                                                                                                                                     High = score 4--12                                                                                                   Multivariate analysis   

  Lin et al[@b50-cmar-9-821]         2013   Breast cancer                              China         82            NA                                              TNM I--IV                                         IHC             Intensity scores: low: 0--2, high: 3--6                      NA                                            OS        Univariate analysis\    7
                                                                                                                                                                                                                                                                                                                                                          Multivariate analysis   

  Liu et al[@b13-cmar-9-821]         2013   Cervical cancer                            China         160           43.6 ± 11.5                                     FIGO stage                                        IHC             Low = score 0\                                               60 (9.6--82.5)                                OS\       Univariate analysis\    9
                                                                                                                                                                                                                                     High = score 1--9                                                                                          PFS       Multivariate analysis   

  Mühlmann et al[@b44-cmar-9-821]    2008   Gastric carcinoma                          Austrian      104           67 (30--94)                                     TNM I--IV                                         IHC             Low = score 0--4\                                            Intestinal-type carcinoma 52\                 OS\       Univariate analysis\    9
                                                                                                                                                                                                                                     High = score 5--12                                           (1--163); diffuse-type carcinoma 16 (1--54)   DFS       Multivariate analysis   

  Ning[@b45-cmar-9-821]              2012   Hilar cholangiocarcinoma                   China         70            59 (39--79)                                     TNM I--IV                                         IHC\            Low = score 0--4\                                            37 (5--115)                                   OS        Univariate analysis\    9
                                                                                                                                                                                                                     QRT-PCR         High = score 5--12                                                                                                   Multivariate analysis   

  Ohmachi et al[@b46-cmar-9-821]     2006   Colorectal cancer                          Japan         74            High 66.6 ± 3.8\                                NA                                                QRT-PCR (74)\   \>95% of the expression values of the normal samples         NA                                            OS        Univariate analysis\    7
                                                                                                                   Low 67.5 ± 2.8                                                                                    IHC (34)                                                                                                                             Multivariate analysis   

  Pak et al[@b15-cmar-9-821]         2012   Lung cancer: NSCLC (ADC and SqCC)          South Korea   164           63.4 (42--81)                                   TNM I--IV                                         IHC             Low = score 0--4\                                            39.4 (1--123)                                 OS\       Multivariate analysis   7
                                                                                                                                                                                                                                     High = score 5--12                                                                                         DFS                               

  Wu[@b61-cmar-9-821]                2012   Laryngeal squamous cell carcinoma          China         109           60.8 (29--87)                                   TNM I--IV                                         IHC\            Low = score 0\                                               35.1 (42.9 ± 29.9)                            OS        Univariate analysis\    9
                                                                                                                                                                                                                     QRT-PCR         High = score 1--9                                                                                                    Multivariate analysis   

  Xu[@b62-cmar-9-821]                2009   Colon cancer                               China         80            High 58.9 ± 11.2\                               TNM II III                                        QRT-PCR         The median of the expression level of colorectal carcinoma   38.5 (7--71)                                  OS        Univariate analysis\    6
                                                                                                                   Low 57.0 ± 11.0                                                                                                                                                                                                                        Multivariate analysis   

  Xu et al[@b56-cmar-9-821]          2016   Ovarian carcinoma                          China         128           52.6 (25--82)                                   FIGO stage WHO                                    IHC             Low = score 0--4\                                            NA                                            OS\       Univariate analysis\    8
                                                                                                                                                                                                                                     High = score 5--12                                                                                         DFS       Multivariate analysis   

  Yuan et al[@b58-cmar-9-821]        2015   Bladder cancer                             China         112           Team A (34--91)\                                TNM I--IV                                         IHC             Low = score 0--4\                                            NA                                            DR        Univariate analysis\    7
                                                                                                                   Team B (49--84)                                                                                                   High = score 5--9                                                                                                    Multivariate analysis   

  Zhang et al[@b57-cmar-9-821]       2017   Bladder cancer NMIBC                       China         102           66.1 (41--88)                                   TNM Ta T1                                         IHC             Low IS ≤ 1\                                                  47 (6--103)                                   DR\       Univariate analysis\    8
                                                                                                                                                                                                                                     High IS = 2--9\                                                                                            PFS       Multivariate analysis   
                                                                                                                                                                                                                                     IS:staining index                                                                                                                            

  Zhao[@b63-cmar-9-821]              2016   Colon cancer                               China         47            35--90 (61.6 ± 9.8)                             Dukes stage A--D                                  IHC             Low = score 0--3\                                            NA                                            OS        Univariate analysis\    7
                                                                                                                                                                                                                                     High = score 4--9                                                                                                    Multivariate analysis   

  Zhao[@b64-cmar-9-821]              2015   Gastric cancer                             China         600           NA                                              TNM I--IV                                         IHC\            Low = score 0--130\                                          NA                                            OS        Univariate analysis\    6
                                                                                                                                                                                                                     QRT-PCR         High = score 131--300                                                                                                Multivariate analysis   
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:** TIS = PS × IS.

**Abbreviations:** NOS, Newcastle--Ottawa Scale; FIGO, International Federation of Gynecology and Obstetrics; WHO, World Health Organization; AJCC, The American Joint Committee on Cancer; ADC, adenocarcinoma; CSS, cancer-specific survival; DR, disease recurrence; IHC, immunohistochemistry; HGNET, high-grade neuroendocrine tumor; DFS, disease-free survival; QRT-PCR, quantitative real-time--polymerase chain reaction; SqCC, squamous cell carcinoma; NSCLC, non-small-cell lung cancer; NMIBC, non-muscle invasive bladder cancer; NA, not available; OS, overall survival; PFS, progression-free survival; TIS, total immunostaining score; PS, proportion score; IS, intensity score.

###### 

Results of meta-analysis

  Overall survival                                                    Number of studies   Number of patients   Pooled HR (95% CI)      *I*-squared (*I*^2^)   Chi-squared heterogeneity test (P)   Analysis model
  ------------------------------------------------------------------- ------------------- -------------------- ----------------------- ---------------------- ------------------------------------ ----------------
  Overall                                                             26                  4566                 **1.84 (1.45--2.35)**   67.3%                  **0.000**                            Random
  Subgroup                                                                                                                                                                                         
  Austria                                                             3                   391                  **1.96 (1.39--2.76)**   0.0%                   0.762                                Random
  China                                                               14                  2312                 **2.26 (1.74--2.93)**   43.0%                  **0.044**                            Random
  Italy                                                               3                   909                  1.21 (0.39--3.76)       84.9%                  **0.001**                            Random
  Japan                                                               5                   790                  1.27 (0.70--2.33        76.8%                  **0.002**                            Random
  South Korea                                                         1                   164                  --                      --                     --                                   --
  Without Ambrogi[@b49-cmar-9-821]                                    25                  3864                 **1.94 (1.58--2.39)**   51.8%                  **0.002**                            Random
  Without Ambrogi[@b49-cmar-9-821] and Inamura (c)[@b55-cmar-9-821]   24                  3749                 **2.00 (1.68--2.36)**   28.1%                  0.100                                Random
  Outcomes                                                                                                                                                                                         
  DFS                                                                 6                   661                  **2.77 (1.73--4.42)**   20.8%                  0.277                                Random
  PFS                                                                 5                   666                  **1.71 (1.25--2.35)**   0.0%                   0.809                                Random
  DR                                                                  4                   1536                 1.44 (0.59--3.52)       86.7%                  **0.000**                            Random
  CSS                                                                 3                   586                  0.65 (0.24--1.76)       75.7%                  **0.016**                            Random
  DFS/PFS                                                             1                   72                   --                      --                     --                                   --
  Characteristics                                                                                                                                                                                  
  Age: (elderly/nonelderly)                                           20                  2783                 0.94 (0.79--1.11)       0.0%                   0.778                                Fixed
  Differentiation: (moderate + poor/well)                             16                  2237                 **3.03 (1.99--4.63)**   61.2%                  **0.001**                            Random
  Distant metastasis: (present/absent)                                5                   970                  **2.46 (1.05--5.75)**   52.7%                  0.076                                Random
  Lymph node metastasis: (present/absent)                             17                  2081                 **2.47 (1.72--3.56)**   59.9%                  **0.001**                            Random
  TNM stage: (III + IV/I + II)                                        15                  2243                 **2.02 (1.38--2.95)**   59.9%                  **0.002**                            Random
  Sex: (male/female)                                                  19                  2627                 1.08 (0.90--1.29)       0.0%                   0.659                                Fixed

**Note:** Bold values indicate statistical significance.

**Abbreviations:** CI, confidence interval; TNM, The TNM Classification of Malignant Tumours; CSS, cancer-specific survival; DR, disease recurrence; DFS, disease-free survival; HR, hazard ratio; PFS, progression-free survival.

###### 

Relationship between TROP2 overexpression and clinical characteristics

  Comparison basis                         Sex (male vs female)   Age (elderly vs nonelderly)   Lymph node metastasis (present vs absent)   Distant metastasis (present vs absent)   TNM stage (III + IV vs I + II)   Differentiation (moderate + poor vs well)                                                                                                     
  ---------------------------------------- ---------------------- ----------------------------- ------------------------------------------- ---------------------------------------- -------------------------------- ------------------------------------------- ----- ----- ----- ----- ----- ----- ---- ---- ----- ----- ----- ---- ----- ----- ----- ----- ---- ----
  Study ID                                 a1                     a0                            b1                                          b0                                       a1                               a0                                          b1    b0    a1    a0    b1    b0    a1   a0   b1    b0    a1    a0   b1    b0    a1    a0    b1   b0
  Bignotti et al (2010)[@b34-cmar-9-821]   --                     --                            --                                          --                                       16                               35                                          1     4     6     6     7     24    --   --   --    --    --    --   --    --    --    --    --   --
  Bignotti et al (2012)[@b35-cmar-9-821]   --                     --                            --                                          --                                       13                               54                                          12    39    5     10    16    63    --   --   --    --    --    --   --    --    --    --    --   --
  Chen et al (2014)[@b36-cmar-9-821]       27                     21                            25                                          20                                       34                               27                                          18    14    36    17    16    24    --   --   --    --    21    7    31    34    29    14    23   27
  Fong et al (2008)[@b39-cmar-9-821]       60                     51                            49                                          37                                       62                               51                                          47    37    70    41    31    34    17   8    61    56    34    12   68    66    93    64    7    17
  Fong et al (2008)[@b40-cmar-9-821]       --                     --                            --                                          --                                       27                               23                                          25    15    23    13    23    19                          46    30   6     8     --    --    --   --
  Guan et al (2015)[@b41-cmar-9-821]       28                     14                            11                                          5                                        20                               9                                           19    10    29    8     10    11    7    5    32    14    27    12   12    7     --    --    --   --
  Inamura (a) (2017)[@b55-cmar-9-821]      104                    40                            68                                          58                                       109                              65                                          63    33    --    --    --    --    --   --   --    --    85    33   87    65    107   49    64   49
  Inamura (b) (2017)[@b55-cmar-9-821]      131                    44                            19                                          7                                        136                              44                                          14    7     --    --    --    --    --   --   --    --    64    20   86    31    131   49    16   1
  Inamura (c) (2017)[@b55-cmar-9-821]      18                     75                            3                                           19                                       17                               70                                          4     24    --    --    --    --    --   --   --    --    13    48   8     45    --    --    --   --
  Jiang et al (2013)[@b48-cmar-9-821]      14                     12                            32                                          29                                       25                               22                                          21    19    39    24    7     17    --   --   --    --    --    --   --    --    29    12    17   29
  Kobayashi (2010)[@b43-cmar-9-821]        43                     19                            44                                          24                                       42                               28                                          45    15    27    14    60    29    --   --   --    --    --    --   --    --    --    --    --   --
  Li (2017)[@b60-cmar-9-821]               6                      15                            25                                          42                                       23                               45                                          8     12    21    5     10    52    --   --   --    --    24    12   7     45    28    6     3    51
  Lin et al (2013)[@b50-cmar-9-821]        --                     --                            --                                          --                                       --                               --                                          --    --    22    1     22    37    11   1    33    37    14    0    30    38    39    24    5    14
  Liu et al (2013)[@b13-cmar-9-821]        --                     --                            --                                          --                                       57                               6                                           37    6     --    --    --    --    --   --   --    --    6     0    88    12    66    5     28   7
  Mühlmann et al (2008)[@b44-cmar-9-821]   40                     23                            13                                          12                                       --                               --                                          --    --    29    23    24    12    7    2    46    33                           52    33    1    2
  Ning et al (2013)[@b45-cmar-9-821]       26                     18                            17                                          9                                        22                               14                                          21    13    --    --    --    --    --   --   --    --    18    17   24    11    22    6     21   21
  Ohmachi et al (2006)[@b46-cmar-9-821]    14                     30                            12                                          18                                       --                               --                                          --    --    14    17    12    31    --   --   --    --                           20    30    6    18
  Pak et al (2012)[@b15-cmar-9-821]        13                     39                            10                                          38                                       --                               --                                          --    --    --    --    --    --    --   --   --    --    8     24   15    53    18    40    5    37
  Wu (2012)[@b61-cmar-9-821]               95                     12                            2                                           0                                        59                               5                                           38    7     18    1     79    11    --   --   --    --    39    5    58    7     57    1     40   11
  Xu (2009)[@b62-cmar-9-821]               21                     19                            19                                          21                                       --                               --                                          --    --    23    17    17    23    --   --   --    --    --    --   --    --    31    27    9    13
  Xu et al (2016)[@b56-cmar-9-821]         --                     --                            --                                          --                                       44                               34                                          31    19    28    12    39    40    --   --   --    --    --    --   --    --    --    --    --   --
  Yuan (2015)[@b58-cmar-9-821]             26                     41                            5                                           11                                       19                               24                                          12    28    --    --    --    --    --   --   --    --    --    --   --    --    --    --    --   --
  Zhang et al (2017)[@b57-cmar-9-821]      30                     37                            20                                          15                                       32                               30                                          18    22    --    --    --    --    --   --   --    --    --    --   --    --    --    --    --   --
  Zhao (2016)[@b63-cmar-9-821]             48                     4                             27                                          3                                        41                               2                                           34    5     41    1     34    6     --   --   --    --    43    1    32    6     54    4     21   3
  Zhao (2015)[@b64-cmar-9-821]             280                    148                           118                                         54                                       168                              98                                          230   104   271   102   127   100   34   4    364   198   203   60   195   142   325   149   29   28

**Notes:** a1: the number of TROP2 overexpression of each former group; a0: the number of normal/low expression of TROP2 of each former group; b1: the number of TROP2 overexpression of each later group; and b0: the number of normal/low expression of TROP2 of each later group.

**Abbreviation:** TNM, The TNM Classification of Malignant Tumours; TROP2, trophoblast cell surface antigen 2.

[^1]: These authors contributed equally to this work
